Cathepsin D as biomarker in CSF of nusinersen‐treated patients with spinal muscular atrophy

to connected objects

Abstract: Background
The therapeutic landscape of spinal muscular atrophy (SMA) has changed dramatically during the last 4 years but treatment responses differ remarkably between individuals and therapeutic decision-making remains challenging - underlining the persistent need for validated biomarkers.

Methods
We applied untargeted proteomic analyses to determine biomarkers in cerebrospinal fluid (CSF) samples of SMA patients under treatment with nusinersen. Identified candidate proteins were validated in CSF samples of SMA patients by Western blot and ELISA. Further, levels of peripheral neurofilament H and L were determined.

Results
Untargeted proteomic analysis of CSF samples of 3 SMA type 1 patients revealed the lysosomal protease Cathepsin D as a candidate biomarker. Subsequent validation analysis in a larger cohort of 31 pediatric SMA patients (type 1=12, type 2=9, type 3=6, presymptomatically treated=4; age 0-16 years) revealed a significant decline of Cathepsin D levels in SMA patients ≥2 months at the start of treatment. While evident in all older age categories, this decline was only significant in the group of patients that showed a positive motor-response. Moreover, downregulation of Cathepsin D was evident in muscle biopsies of SMA patients.

Conclusions
We identified a decline of Cathepsin D levels in CSF samples of SMA patients under nusinersen treatment that was more pronounced in the group of ‘treatment responders’ than in ‘non-responders’. We believe that our results indicate a suitability of Cathepsin D levels as possible biomarker in SMA also in older patients – in combination with analysis of pNF-L in adolescents or alone in adult patients

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
Online-Ressource
Language
Englisch
Notes
European journal of neurology. - 29, 7 (2022) , 2084-2096, ISSN: 1468-1331

Classification
Medizin, Gesundheit

Event
Veröffentlichung
(where)
Freiburg
(who)
Universität
(when)
2022
Creator

DOI
10.1111/ene.15331
URN
urn:nbn:de:bsz:25-freidok-2259075
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
25.03.2025, 1:50 PM CET

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

Time of origin

  • 2022

Other Objects (12)

Routine cerebrospinal fluid (CSF) parameters in patients with spinal muscular atrophy (SMA) treated with nusinersen

Routine cerebrospinal fluid (CSF) parameters in patients with spinal muscular atrophy (SMA) treated with nusinersen

Pattern of pareses in 5q-spinal muscular atrophy

Pattern of pareses in 5q-spinal muscular atrophy

Diagnosis and management of spinal muscular atrophy : : Part 2

Diagnosis and management of spinal muscular atrophy : : Part 2

Risdiplam in patients previously treated with other therapies for spinal muscular atrophy: an interim analysis from the JEWELFISH study

Risdiplam in patients previously treated with other therapies for spinal muscular atrophy: an interim analysis from the JEWELFISH study

Real-world outcomes in patients with spinal muscular atrophy treated with onasemnogene abeparvovec monotherapy: findings from the RESTORE Registry

Real-world outcomes in patients with spinal muscular atrophy treated with onasemnogene abeparvovec monotherapy: findings from the RESTORE Registry

Defective Mitochondria Contribute to Impaired Translation in Spinal Muscular Atrophy

Defective Mitochondria Contribute to Impaired Translation in Spinal Muscular Atrophy

Cytoskeletal dysregulation in the motoneuron disease Spinal Muscular Atrophy (SMA)

Hochschulschrift

Cytoskeletal dysregulation in the motoneuron disease Spinal Muscular Atrophy (SMA)

Molecular mechanisms of cytoskeletal dysregulations in Spinal Muscular Atrophy (SMA)

Molecular mechanisms of cytoskeletal dysregulations in Spinal Muscular Atrophy (SMA)

Costs of illness of spinal muscular atrophy: a systematic review

Costs of illness of spinal muscular atrophy: a systematic review

Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy

Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy

Correction to: Risdiplam inpatients previously treated with other therapies for spinal muscular atrophy: an interim analysis from the JEWELFISH study

Correction to: Risdiplam inpatients previously treated with other therapies for spinal muscular atrophy: an interim analysis from the JEWELFISH study

J wave syndromes in patients with spinal and bulbar muscular atrophy

J wave syndromes in patients with spinal and bulbar muscular atrophy

Related objects